Document Detail


Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells.
MedLine Citation:
PMID:  11707844     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rituximab 375 mg/m(2) weekly x 4 has been reported to induce a 60% response rate in patients with relapsed follicular lymphomas (FL). Our aim was to examine the effect of this rituximab schedule on circulating FL cells in an ongoing multicenter study. One hundred fifty-four patients with FL were examined by nested polymerase chain reaction (PCR) at baseline for the presence of t(14;18) translocation-carrying lymphoma cells in bone marrow and/or blood. Sixty-four patients (42%) had PCR-detectable t(14;18)(+) FL cells. Pretreatment characteristics of these 64 patients were as follows: one had stage I, nine had stage II, 14 had stage III, and 40 had stage IV disease. Thirty-five patients had bulky disease (> or = 5 cm) and 25 patients had an elevated serum lactate dehydrogenase (LDH) level. Bone marrow was morphologically assessed in 64 patients, and 39 of these patients had an infiltration with FL cells. Blood samples from 51 patients were available for PCR analysis between weeks 8-12 after induction therapy, and 28 of these patients (55%) were PCR negative. Paired blood and bone marrow samples were available for PCR analysis from 39 patients between weeks 8-12 after induction therapy with rituximab. Thirteen of these patients (33%) did not have PCR-detectable cells in blood and bone marrow, while 26 patients (67%) still had circulating t(14;18)(+) cells in either bone marrow (eight patients), blood (one patient), or both (17 patients). PCR negativity in blood and bone marrow in 13 patients was statistically significantly associated with partial or complete response after induction therapy with rituximab (P = 0.006). However, clearance of PCR-detectable t(14;18)(+) cells in bone marrow and/or blood could not be associated with any low tumor burden pretreatment characteristics such as stages I/II, absence of morphological bone marrow infiltration or tumor bulk of > or = 5 cm, and normal serum LDH.
Authors:
G Pichert; S F Schmitz; U Hess; T Cerny; S B Cogliatti; D Betticher; R Stupp; D Schmitter; R A Stahel; M Ghielmini
Related Documents :
18616874 - Spectrum of pure red cell aplasia in adult population of north-west india.
897164 - The use of rare-earth radionuclides and other bone-seekers in the evaluation of bone le...
2702504 - Skeletal lymphoma.
9678534 - Markers of bone turnover in patients with differentiated thyroid cancer with and follow...
23209894 - Differential short-term repeated forearm hyperaemic reactivity in coronary artery disea...
9717894 - Doppler echocardiography in suspected lone atrial fibrillation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical lymphoma     Volume:  1     ISSN:  1526-9655     ISO Abbreviation:  Clin Lymphoma     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-11-14     Completed Date:  2002-01-23     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  100898741     Medline TA:  Clin Lymphoma     Country:  United States    
Other Details:
Languages:  eng     Pagination:  293-7     Citation Subset:  IM    
Affiliation:
Division of Oncology, The Swiss Group for Clinical Cancer Research, University Hospital, Ramistrasse, Zurich, Switzerland. onkpib@usz.unizh.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / immunology*
Antineoplastic Agents / therapeutic use*
Chromosomes, Human, Pair 14 / genetics*
Chromosomes, Human, Pair 18 / genetics*
Cytogenetic Analysis
Drug Administration Schedule
Female
Humans
L-Lactate Dehydrogenase / metabolism
Lymphoma, B-Cell / blood,  drug therapy*,  enzymology,  genetics
Lymphoma, Follicular / blood,  drug therapy*,  enzymology,  genetics
Male
Middle Aged
Neoplasm Staging
Neoplastic Cells, Circulating / drug effects*
Polymerase Chain Reaction
Translocation, Genetic
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD20; 0/Antineoplastic Agents; 0/rituximab; EC 1.1.1.27/L-Lactate Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and ...
Next Document:  Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK...